TLSI today
$2.27-$0.03 (-1.30%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourExpanding
1 hourDescending Triangle
15 minLeaning Bullish
5 minStrong Bearish
Daily trend turns down below $9.45
Key levels
Resistance$10.21
Resistance$9.61
Latest news & SEC filings
AnalystH.C. Wainwright repeats positive stance on TriSalus Life Sciences, revises target
AnalystCanaccord Genuity keeps Buy rating on TriSalus Life Sciences, cuts target to $4
AnalystHC Wainwright keeps Buy rating on TriSalus Life Sciences, cuts target to $10
All TLSI news →About TriSalus Life Sciences
TriSalus Life Sciences is a medical device and drug development company. It sells the TriNav infusion system, used by physicians and hospitals to deliver therapies to liver and pancreatic tumors. The company is also developing nelitolimod, an investigational immunotherapy delivered through its platform. It operates in the United States and relies on third-party suppliers and manufacturers.
Based on the company's 10-K filed Mar 5, 2026.
Nasdaq · Healthcare
TriSalus Life Sciences, Inc. (TLSI)
What Is the Price Target for TLSI?
SEPT Low Target
$12.00
SEPT Mid Target
$12.00
SEPT High Target
$12.00
Analyst Consensus
$12.00
Is TLSI a Buy or Sell Right Now?
Thesis
- •Revenue growing 53.4% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 2 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TLSI.
Start Free Trial →Is TLSI Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$9.07
35
Moat Score
NONE
5/9
Piotroski Score
-12.6
Altman Z-Score
What Is Smart Money Doing with TLSI?
Insider Signal
NEUTRAL
6 buys / 4 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Szela Mary T | director officer | Sale | 2,693 | $12K | Oct 5, 2026 |
| Cox Bryan F. | officer | Sale | 296 | $1K | Oct 5, 2026 |
| Marshak Richard | officer | Sale | 325 | $1K | Oct 5, 2026 |
| Stevens Jennifer | officer | Sale | 316 | $1K | Oct 5, 2026 |
| Marshak Richard | officer | Sale | 543 | $1K | May 15, 2026 |
| Wahlstrom Mats | director | Buy | 60,000 | $152K | May 15, 2026 |
| Stansky Michael P | director | Buy | 410,000 | $1.0M | May 15, 2026 |
| Stansky Michael P | director | Buy | 200,000 | $500K | May 15, 2026 |
| Szela Mary T | director officer | Buy | 39,682 | $103K | May 15, 2026 |
| Patience David | officer | Buy | 7,100 | $17K | May 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →TLSI Growth Story
Revenue YoY
53.4%
3yr Revenue CAGR
53.9%
EPS Growth YoY
-40.46%
FCF Growth YoY
54.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for TLSI
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for TLSI, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:41:47 | $2.36 | 7,177 | $$17K | SELL |
| 14:41:40 | $2.45 | 9,000 | $$22K | BUY |
| 14:41:29 | $2.37 | 3,500 | $$8K | BUY |
| 14:41:27 | $2.37 | 1,400 | $$3K | BUY |
| 14:41:17 | $2.33 | 1,000 | $$2K | BUY |
5 dark pool trades shown · $$53K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for TriSalus Life Sciences, Inc. (TLSI) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (5 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →TLSI — frequently asked questions
What is TLSI stock price today?
TriSalus Life Sciences, Inc. (TLSI) is at $2.27, down 1.30% (-$0.03) at the Nov 12, 2026 close.
Why is TLSI stock moving today?
Latest TLSI news — Nov 12, 2026: H.C. Wainwright repeats positive stance on TriSalus Life Sciences, revises target · Nov 11, 2026: Canaccord Genuity keeps Buy rating on TriSalus Life Sciences, cuts target to $4
Why did TLSI stock move on Nov 10, 2026?
TriSalus Life Sciences reported Q3 2026 financial results, posting a wider quarterly loss of $0.15 per share that missed the $0.13 loss expected, while revenue of $12.900 million fell short of the $14.024 million estimate. The company also cut its FY2026 sales guidance to $46M-$48M from a prior $54M-$57M, well below the $53.119 million analysts had expected.
What is the TLSI price target?
The average analyst price target for TLSI is $12.00, ranging from $12 to $12, based on 1 analysts. Latest: HC Wainwright & Co. maintains on Sep 23, 2026.
What do analysts rate TLSI?
Analyst ratings for TLSI: 0 Buy, 2 Hold, 0 Sell — consensus Hold.
Did TLSI beat earnings?
TLSI last reported on Nov 10, 2026: EPS -$0.15 vs -$0.13 expected — a miss of 15.4%.
Does TLSI pay a dividend?
TLSI does not currently pay a dividend.
What are TLSI support and resistance levels?
Resistance: $9.61, $10.21.
What are insiders doing with TLSI?
Insider activity: NEUTRAL, 6 buys and 4 sells in the last 90 days.
What is the latest news on TLSI?
Nov 12, 2026: H.C. Wainwright repeats positive stance on TriSalus Life Sciences, revises target · Nov 11, 2026: Canaccord Genuity keeps Buy rating on TriSalus Life Sciences, cuts target to $4 · Nov 11, 2026: HC Wainwright keeps Buy rating on TriSalus Life Sciences, cuts target to $10